CN115943153A - 用于治疗阿尔茨海默病的化合物和方法 - Google Patents

用于治疗阿尔茨海默病的化合物和方法 Download PDF

Info

Publication number
CN115943153A
CN115943153A CN202180008401.XA CN202180008401A CN115943153A CN 115943153 A CN115943153 A CN 115943153A CN 202180008401 A CN202180008401 A CN 202180008401A CN 115943153 A CN115943153 A CN 115943153A
Authority
CN
China
Prior art keywords
seq
leu
monomer
amino acid
ile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180008401.XA
Other languages
English (en)
Chinese (zh)
Inventor
扬·约翰逊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AlphaBeta AB
Original Assignee
AlphaBeta AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AlphaBeta AB filed Critical AlphaBeta AB
Publication of CN115943153A publication Critical patent/CN115943153A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Psychiatry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202180008401.XA 2020-01-08 2021-01-07 用于治疗阿尔茨海默病的化合物和方法 Pending CN115943153A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20150738 2020-01-08
EP20150738.1 2020-01-08
PCT/EP2021/050168 WO2021140140A1 (en) 2020-01-08 2021-01-07 Compound and method for treatment of alzheimer's disease

Publications (1)

Publication Number Publication Date
CN115943153A true CN115943153A (zh) 2023-04-07

Family

ID=69156193

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180008401.XA Pending CN115943153A (zh) 2020-01-08 2021-01-07 用于治疗阿尔茨海默病的化合物和方法

Country Status (5)

Country Link
US (1) US20230002458A1 (https=)
EP (1) EP4087860B1 (https=)
JP (1) JP7820821B2 (https=)
CN (1) CN115943153A (https=)
WO (1) WO2021140140A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024079221A1 (en) 2022-10-12 2024-04-18 Alphabeta Ab The bri2 brichos domain for delivery of proteins into cns neurons
WO2025078660A1 (en) 2023-10-11 2025-04-17 Alphabeta Ab The bri2 brichos domain for treatment of parkinson´s disease

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1286697A (zh) * 1998-12-10 2001-03-07 上海第二医科大学 Npcahh01:人跨膜蛋白e3－16基因
CN101365471A (zh) * 2005-06-14 2009-02-11 犹太大学阿尔伯特爱因斯坦医学院 BRI蛋白对Aβ产生的影响
WO2012138284A1 (en) * 2011-04-05 2012-10-11 Alphabeta Ab Amyloidosis target useful in methods of treatment and for screening of compounds

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010356144B2 (en) 2010-06-24 2015-06-04 Alphabeta Ab Compound and method for treatment of Alzheimer's disease and familial dementia

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1286697A (zh) * 1998-12-10 2001-03-07 上海第二医科大学 Npcahh01:人跨膜蛋白e3－16基因
CN101365471A (zh) * 2005-06-14 2009-02-11 犹太大学阿尔伯特爱因斯坦医学院 BRI蛋白对Aβ产生的影响
WO2012138284A1 (en) * 2011-04-05 2012-10-11 Alphabeta Ab Amyloidosis target useful in methods of treatment and for screening of compounds

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"integral membrane protein 2B [Erpetoichthys calabaricus]", NCBI:BLAST, 21 April 2019 (2019-04-21) *
SANCHEZ-PULIDO L等: "BRICHOS: a conserved domain in proteins associated with dementia, respiratory distress and cancer", TRENDS IN BIOCHEMICAL SCIENCES, vol. 27, no. 7, 1 July 2002 (2002-07-01), pages 329 - 332, XP004369724, DOI: 10.1016/S0968-0004(02)02134-5 *
WEI, Q.: "Draft Genome and Complete Hox-Cluster Characterization of the SterletRT Sturgeon (Acipenser ruthenus).", UNIPROT, 8 May 2019 (2019-05-08) *

Also Published As

Publication number Publication date
EP4087860C0 (en) 2023-11-22
JP7820821B2 (ja) 2026-02-26
EP4087860B1 (en) 2023-11-22
WO2021140140A1 (en) 2021-07-15
JP2023509187A (ja) 2023-03-07
US20230002458A1 (en) 2023-01-05
EP4087860A1 (en) 2022-11-16

Similar Documents

Publication Publication Date Title
Souchet et al. Inhibition of DYRK1A proteolysis modifies its kinase specificity and rescues Alzheimer phenotype in APP/PS1 mice
Jawhar et al. Pyroglutamate amyloid-β (Aβ): a hatchet man in Alzheimer disease
EP2209485B1 (en) Extracellular histones as biomarkers for prognosis and molecular targets for therapy
RU2769701C2 (ru) Модуляторы активности комплемента
CN111683672A (zh) 补体活性调节剂
WO2013034982A2 (en) Immunomodulatory peptides for treatment of progressive neurodegenerative diseases
CN101611152A (zh) 用于调控set的方法及其用途
JP2012136536A (ja) アテローム血栓症およびプラーク破壊を予防するためのアネキシンｖ
Mazzitelli et al. Amyloid-β 1–24 C-terminal truncated fragment promotes amyloid-β 1–42 aggregate formation in the healthy brain
US11613753B2 (en) Methods and pharmaceutical compositions for treating tubulin carboxypeptidases associated diseases
CN115943153A (zh) 用于治疗阿尔茨海默病的化合物和方法
Urbanc Cross-linked amyloid β-protein oligomers: A missing link in Alzheimer’s disease pathology?
KR102488987B1 (ko) 알츠하이머 질환을 치료하는데 사용되는 약물 및 치료 표적제를 스크리닝하는 방법
JP2022501388A (ja) 関節リウマチにおけるｐｔｐｒｓ及びプロテオグリカン
US20220034913A1 (en) Methods and compostions of detecting and treating neurodegenerative disorders
JP7175608B2 (ja) 加齢に伴うフレイルのための治療としてのオステオカルシン
CN112153897B (zh) 用于治疗神经病学和其他病症的组合物和方法
US20140314790A1 (en) Caspase 9 inhibition and bri2 peptides for treating dementia
Zhang Amyloid Aggregation and Mitigation
Vijayan et al. Osteocalcin modulates Abeta42 aggregation to aid in amyloid reduction in mouse models of Alzheimer's disease
RU2797200C1 (ru) Способы и фармацевтические композиции для лечения заболеваний, связанных с тубулин карбоксипептидазами (tcp)
US20080280824A1 (en) Compositions and methods for treatment of cancer or neurodegenerative disease with peptide based microtubule stabilizers or inhibitors
RU2812207C2 (ru) Способы и фармацевтические композиции для лечения заболеваний, связанных с тубулин карбоксипептидазами (tcp)
Borbély Development of Non-Transgenic Animal Models of Alzheimer’s Disease and Investigation of Drug Candidates for its Treatment
Shahsavani Evaluating the role of Neuregulin-1β1 in neuroprotection after spinal cord injury

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination